Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Dr. Reddy's Laboratories Limited Results of Review of Interim Financial Statements We have reviewed the accompanying c

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc.(Stock Code :RDY)

Sub: Form 6-K for the quarter ended June 30, 2022, filed

with United States Securities and Exchange Commission.

This is to inform you that the Company has filed its

unaudited condensed consolidated interim financial statements prepared under IFRS in Form 6-K for the quarter ended June 30, 2022,

with the United States Securities and Exchange Commission on July 28, 2022. A copy of the Form 6-K is attached. The Form 6-K is

also available on the Company's website, www.drreddys.com.

This is for your information.

For Dr. Reddy's Laboratories Limited

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended June 30, 2022

Commission File Number 1-15182

REDDY'S LABORATORIES LIMITED

(Translation of registrant's name into English)

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports

under cover of Form 20-F or Form 40-F.

Indicate by check mark if the registrant is submitting the Form 6-K in paper

as permitted by Regulation S-T Rule 101(b)(1): ______

Note: Regulation S-T Rule 101(b)(1) only permits the submission in

paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper

as permitted by Regulation S-T Rule 101(b)(7):

Note: Regulation S-T Rule 101(b)(7) only permits

the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer

must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized

(the registrant's "home country"), or under the rules of the home country exchange on which the registrant's

securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed

to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission

or other Commission filing on EDGAR.

Quarter Ended June 30, 2022

Currency of Presentation and Certain Defined Terms

In this Quarterly Report, references

to "$" or "dollars" or "U.S.$" or "U.S. dollars" are to the legal currency of the

United States, and references to "Rs." or "rupees" or "Indian rupees" or "INR"

are to the legal currency of India, references to "MXN" are to the legal currency of Mexico, references to "ZAR"

are to the legal currency of South Africa, references to "UAH" are to the legal currency of Ukraine, references to

"GBP" are to the legal currency of the United Kingdom, references to "RUB" or "rouble" or "ruble"

are to the legal currency of the Russian Federation and references to "EUR" or "euros" are to the legal

currency of the European Union. Our unaudited condensed consolidated interim financial statements are presented in Indian rupees

and are prepared in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS

34"). Convenience translation into U.S. dollars with respect to our unaudited condensed consolidated interim financial statements

is also presented. References to a particular "fiscal" year are to our fiscal year ended March 31 of such year. References

to "ADSs" are to our American Depositary Shares. All references to "IAS" are to the International Accounting

Standards, to "IASB" are to the International Accounting Standards Board, to "IFRS" are to International

Financial Reporting Standards as issued by the IASB, to "SIC" are to the Standing Interpretations Committee and to

"IFRIC" are to the International Financial Reporting Interpretations Committee. References to "FVTOCI" are

to fair value through other comprehensive income and to "FVTPL" are to fair value through profit and loss.

References to "U.S. FDA"

are to the United States Food and Drug Administration, to "ANDS" are to Abbreviated New Drug Submissions, to "NDAs"

are to New Drug Applications, and to "ANDAs" are to Abbreviated New Drug Applications.

References to "U.S."

or "United States" are to the United States of America, its territories and its possessions. References to "India"

are to the Republic of India. References to "EU" are to the European Union. All references to "we", "us",

"our", "DRL", "Dr. Reddy's" or the "Company" shall mean Dr. Reddy's

Laboratories Limited and its subsidiaries. "Dr. Reddy's" is a registered trademark of Dr. Reddy's Laboratories

Limited in India. Other trademarks or trade names used in this Quarterly Report are trademarks registered in the name of Dr. Reddy's

Laboratories Limited or are pending before the respective trademark registries, unless otherwise specified. Market share data is

based on information provided by IQVIA Holdings Inc. (formerly Quintiles IMS Holdings Inc.) ("IQVIA"), a provider of

market research to the pharmaceutical industry, unless otherwise stated.

Our unaudited condensed consolidated

interim financial statements are presented in Indian rupees and translated into U.S. dollars for the convenience of the reader.

Except as otherwise stated in this report, all convenience translations from Indian rupees to U.S. dollars are at the certified

foreign exchange rate of U.S.$1.00 = Rs.79.02, as published by Federal Reserve Board of Governors on June 30, 2022. No

representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such

a rate or any other rate. Any discrepancies in any table between totals and sums of the amounts listed are due to rounding.

Our main corporate website address

is https://www.drreddys.com. Information contained in our website, www.drreddys.com, is not part of this Quarterly Report and no

portion of such information is incorporated herein.

Forward-Looking Statements and Risk Factor Summary

In addition to historical information,

this quarterly report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,

as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In addition to

statements which are forward-looking by reason of context, the words "may", "will", "should",

"expects", "plans", "intends", "anticipates", "believes", "estimates",

"predicts", "potential", or "continue" and similar expressions identify forward-looking statements.

The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results

to differ materially from those reflected in the forward-looking statements. Factors that might cause such a difference include,

but are not limited to, risks relating to:

Readers are cautioned not to place

undue reliance on these forward-looking statements, which reflect management's analysis and assumptions only as of the date

hereof. In addition, readers should carefully review the other information in this quarterly report, in our most recent Annual

Report on Form 20-F for the year ended March 31, 2022 and in our periodic reports and other documents filed with and/or furnished

to the SEC from time to time.

ITEM 1. FINANCIAL STATEMENTS

DR. REDDY'S LABORATORIES

LIMITED AND SUBSIDIARIES

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS

OF FINANCIAL POSITION

(in millions, except share and per share data)